TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Stock
TEVA has an Alpha Score of 25 out of 100 (poor), computed on Nov 6, 2026 from 3 of 4 sub-scores. 8 members of Congress disclosed 10 trades in TEVA since 2014: 3 purchases and 7 sales, most recently Alan Armstrong (purchase, Mar 30, 2026). 7 of the hedge funds AlphaScala tracks reported TEVA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $110.63M. Company insiders reported 0 open-market buys and 11 sales on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 68.0 and its net margin 4.1% (key statistics as of Nov 4, 2026).
What is TEVA's Alpha Score?
How it works →Alpha Score of 25 reflects poor overall profile with weak momentum, poor value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)?
Most recent: Alan Armstrong (purchase, Mar 30, 2026); records start Dec 19, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Alan Armstrong R-OK · Senate | 2026-03-30 | purchase | $1k – $15k |
| Greg Gianforte R-MT · House | 2020-11-13 | purchase | $15k – $50k |
| Donna Shalala D-FL · House | 2020-05-07 | sale | $1k – $15k |
| Patty Murray D-WA · Senate | 2017-06-15 | sale | $1k – $15k |
| Angus King I-ME · Senate | 2016-10-19 | sale | $1k – $15k |
| Mike Conaway R-TX · House | 2016-09-12 | sale | $1k – $15k |
| Mike Conaway R-TX · House | 2016-05-04 | sale | $1k – $15k |
| Mike Conaway R-TX · House | 2015-02-09 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all TEVA political trades →Which hedge funds own TEVA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 3.27M | $110.63M | +72% |
| Greenlight Capital David Einhorn | 2.89M | $97.78M | -1% |
| Bridgewater Associates Ray Dalio | 1.33M | $44.95M | +18% |
| Point72 Steve Cohen | 1.06M | $35.91M | -6% |
| Duquesne Family Office Stanley Druckenmiller | 625K | $21.18M | -74% |
| D.E. Shaw David Shaw | 181K | $6.12M | +29% |
| Citadel Ken Griffin | 73K | $2.48M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are TEVA PHARMACEUTICAL INDUSTRIES LTD insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 5, 26 | Sabag Mark | See "Remarks" | SELL | 46.0K | $1.9M |
| Nov 4, 26 | Bergwerk Dov | Interim Cheif Legal Officer | SELL | 17.5K | $730K |
| Nov 4, 26 | Bergwerk Dov | Interim Cheif Legal Officer | SELL | 8.8K | $365K |
| Sep 18, 26 | Mignone Roberto | Director | SELL | 367.6K | $14.4M |
| Sep 18, 26 | Savage Brian | Interim Chief Legal Officer | SELL | 4.5K | $174K |
| Sep 18, 26 | Savage Brian | Interim Chief Legal Officer | SELL | 2.5K | $99K |
| Sep 18, 26 | Savage Brian | Interim Chief Legal Officer | SELL | 314 | $12K |
| Aug 21, 26 | Satchi-Fainaro Ronit | Director | SELL | 415 | $15K |
| Aug 21, 26 | Weiss Amir | Chief Accounting Officer | SELL | 6.9K | $261K |
| Aug 21, 26 | Weiss Amir | Chief Accounting Officer | SELL | 2.5K | $94K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are TEVA's key statistics?
Key statistics as of Nov 4, 2026
How does TEVA's valuation compare with the Healthcare sector?
| Metric | TEVA | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 68.0 | 28.8 | 111 |
| Net margin | 4.09% | 4.31% | 164 |
| Return on equity | 9.11% | 5.47% | 185 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
AlphaScala analysis on TEVA
Latest 1TEVA price chart
Powered by TradingViewWhat does TEVA PHARMACEUTICAL INDUSTRIES LTD do?
Teva Pharmaceutical Industries Ltd. ADR is an American Depositary Receipt representing shares of the Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd., founded in 1901 and headquartered in Tel Aviv, Israel. The company develops, manufactures, markets, and distributes a broad portfolio of generic medicines and innovative biopharmaceutical products across the United States, Europe, Israel, and international markets. Its generic offerings span various dosage forms including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, creams, sterile products, hormones, high-potency drugs, and cytotoxics, often combined with medical devices. Teva specializes in key therapeutic areas such as the central nervous system with products like COPAXONE for multiple sclerosis, AJOVY for migraine prevention, and AUSTEDO for movement disorders; respiratory treatments including ProAir RespiClick, QVAR RediHaler, and DuoResp Spiromax; and oncology with biosimilars like Truxima and Herzuma, plus BENDEKA and TREANDA injections. Additionally, it supplies active pharmaceutical ingredients, provides contract manufacturing services, and operates a U.S.-based generic and specialty drug distribution platform through Anda. Teva's diverse operations position it as a leading global player in accessible healthcare solutions, serving patients with both cost-effective generics and specialized therapies.